MARKET

EVOK

EVOK

Evoke Pharma Inc
NASDAQ
3.125
-0.015
-0.48%
Opening 13:47 05/14 EDT
OPEN
3.140
PREV CLOSE
3.140
HIGH
3.210
LOW
3.125
VOLUME
2.24K
TURNOVER
--
52 WEEK HIGH
12.32
52 WEEK LOW
1.940
MARKET CAP
4.67M
P/E (TTM)
-1.1123
1D
5D
1M
3M
1Y
5Y
1D
Evoke Pharma, Inc. Q1 Loss Decreases, But Misses Estimates
NASDAQ · 18h ago
Evoke Pharma GAAP EPS of -$0.51 misses by $0.18, revenue of $3.1M misses by $0.22M
Seeking Alpha · 20h ago
Evoke Pharma Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters · 21h ago
EVOKE PHARMA INC: REITERATES ITS 2025 NET PRODUCT SALES GUIDANCE
Reuters · 21h ago
EVOKE PHARMA REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Reuters · 21h ago
Weekly Report: what happened at EVOK last week (0505-0509)?
Weekly Report · 2d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 05/06 21:06
Weekly Report: what happened at EVOK last week (0428-0502)?
Weekly Report · 05/05 11:43
More
About EVOK
More
Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates through the development and commercialization of pharmaceutical products. It is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. It developed Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel formulation of metoclopramide offering systemic delivery by nasal spray administration. It has developed the nasal formulation of metoclopramide to provide its targeted patient population with acute or recurrent symptoms of diabetic gastroparesis.
Recently
Symbol
Price
%Change

Webull offers Evoke Pharma Inc stock information, including NASDAQ: EVOK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EVOK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EVOK stock methods without spending real money on the virtual paper trading platform.